意大利公司 Recordati 以 $825M 的价格收购了 Sanofi 的 Enjaymo，并有可能再以 $250M 的价格收购 CAD 处理，将于 2024 年底完成交易。 Italian company Recordati acquires Sanofi's Enjaymo for $825M, with potential for $250M more, for CAD treatment, closing by end 2024.

意大利制药公司 Recordati 以 8.25 亿美元的价格收购了赛诺菲 Enjaymo 的全球权利，这是 FDA 批准的唯一一种治疗冷凝集素病 （CAD） 的药物，并可能支付高达 2.5 亿美元的里程碑付款。 Italian pharmaceutical company Recordati has acquired the global rights to Sanofi's Enjaymo, the only FDA-approved treatment for cold agglutinin disease (CAD), for $825 million, with up to $250 million in potential milestone payments. 预计这项交易将在2024年底结束,等待条例批准。 The deal is expected to close by the end of 2024, pending regulatory approval. Recordati 计划用现有现金和新的银行债务为此次收购提供资金，同时保持其股息和资本配置政策。 Recordati plans to fund the acquisition with existing cash and new bank debt, while maintaining its dividend and capital allocation policies.